SCHULMAN AMY W 4

What Happened
Amy W. Schulman, a director of Alnylam Pharmaceuticals (ALNY), exercised 11,250 stock options on 2026-05-13, acquiring 11,250 common shares at an exercise price of $70.20 per share for a total cash outlay of $789,750. The filing also records the corresponding derivative (the options) as disposed/cancelled with $0 proceeds — i.e., the options were converted into the underlying shares and cancelled.

Key Details

• Transaction date: 2026-05-13 (reported on Form 4 filed 2026-05-14). Filing appears timely.
• Exercise details: 11,250 shares acquired @ $70.20 = $789,750 (transaction code M: option exercise).
• Derivative entry: 11,250 options reported as disposed @ $0.00 (reflects conversion/cancellation of the options).
• Shares owned after transaction: not specified in the supplied filing details.
• Footnote: the options exercised and held were due to expire on June 3, 2026.

Context
This was an option exercise resulting in ownership of shares (not an immediate sale). For retail investors: option exercises convert the right to buy stock into actual shares — they are acquisitions of stock rather than sell transactions. The filing does not indicate a cashless sale or transfers beyond the conversion of the options.